Morgan Lewis Advises enGene Holdings on $150M Public Offering of Common Shares and Pre-Funded Warrants

BOSTON and NEW YORK, November 14, 2025: Morgan Lewis represented enGene Holdings Inc. in its underwritten public offering of 14,852,940 common shares at a public offering price of $8.50 per share (including 2,294,117 common shares issued pursuant to the exercise of an option granted to the underwriters), as well as prefunded warrants to purchase 2,735,295 of its common shares to a certain investor at an offering price of $8.4999 per prefunded warrant. The gross proceeds to the company were approximately $150 million. The offering closed on November 14 and November 18, with respect to the greenshoe option.

enGene is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. The offering followed the announcement by enGene of positive results from its pivotal LEGEND trial of its lead product candidate in patients with high-risk, BCG-unresponsive NMIBC with CIS, which sparked an increase in its share price.

The Morgan Lewis team advising enGene includes partner Julio Vega with associates David Bionghi, Maria Sasinoski, and Okeya Smith and Tax partners Chuck Bogle and Richard Zarin.